Ann: Results of Meeting, page-67

Six words….corporate governance, risk management , Scorpion Therapeutics. Axel Hoos has been integral to the building of IMU platforms in the way that all the trial protocols were designed to elicit the particular data outcomes that BP ticks boxes on. However, IMU is now an ASX 300 company and is evolving into a bigger entity which brings with it a different level of corporate scrutiny. IMU is now a very commercially sensitive entity.

It’s tough for Hoos but he too has moved up through his new CEO role of a next generation oncology group which poses uncomfortable conflict of interest issues …in addition to his other hats in the same space.

The vote would not have happened out of the blue. There’s always consultations between significant shareholders and the board Chair as to why the major holders have formed a view and their intent to block vote a certain way. IMU holders were lucky to have Hoos on during the build phase.